Erythropoietin as treatment for late hyporegenerative anemia in neonates with Rh hemolytic disease after in utero exchange transfusion.
We report the effects of recombinant human erythropoietin (rHuEPO) in the treatment of late hyporegenerative anemia in 2 neonates with Rh hemolytic disease who had received several in utero exchange transfusions. In both cases anemia occurred at 6 weeks of age and we started therapy at approximately 70 days of age. We used rHuEPO at 250 U/kg three times a week. We also used high-dose intravenous immunoglobulin therapy. One week after initiation of erythropoietin treatment, an increase in reticulocyte count and Hb level was noted in our 2 patients. They did not require further erythrocyte transfusions but they already had received two transfusions after birth. There were no side effects attributable to rHuEPO treatment.
Nicaise
Claire
C
Service de Médecine Infantile et Néonatologie, Hôpital Nord, Marseille, France. cgire@ap-hm.fr
Gire
Catherine
C
Casha
Paul
P
d'Ercole
Claude
C
Chau
Cécile
C
Palix
Christian
C
D000741:Anemia, Aplastic / Q000150:complications* / Q000188:drug therapy*; D001805:Blood Transfusion, Intrauterine; D004921:Erythropoietin / Q000627:therapeutic use*; D005078:Exchange Transfusion, Whole Blood; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012203:Rh Isoimmunization / Q000150:complications* / Q000628:therapy*
D011994:Recombinant Proteins; D004921:Erythropoietin